You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer

    SBC: 7 Hills Pharma LLC            Topic: 102

    DESCRIPTION provided by applicant Recent FDA approvals of ipilimumab nivolumab and pembrolizumab which target checkpoint receptors cytotoxic T lymphocyte associated antigen CTLA and programmed death PD have ushered in a new era of cancer immunotherapy in metastatic melanoma Despite unprecedented overall survival benefits with combination therapy the incidence of complete respo ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Optimization of the Production and Isolation of the Novel Antifungal Occidiofungin

    SBC: Sano Chemicals, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant Occidiofungin is a cyclic nonribosomally synthesized antifungal peptide with submicromolar fungicidal activity against a broad spectrum of fungi Occidiofungin is produced by the Gram negative bacterium Burkholderia contaminans From our structural characterization studies occidiofungin was determined to have a unique chemical composition Our studies have als ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Blood based diagnostics for Alzheimer s Disease

    SBC: Amprion, Inc.            Topic: NIA

    DESCRIPTION provided by applicant This proposal is for a phase I II fast track project for the STTR program with the main goal to develop a blood test for Alzheimerandapos s disease AD diagnosis AD is the most common dementia in the elderly population and one of the leading causes of death in the developed world One of the main problems in AD is the lack of an early sensitive and objective ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Digital Gene Expression Analysis by 3’ End Sequencing

    SBC: BIOO SCIENTIFIC CORPORATION            Topic: 172

    DESCRIPTION provided by applicant A key application of deep sequencing is gene expression analysis at the RNA level commonly known as RNA seq Reads from RNA seq cover all regions of an mRNA sequence However sequences derived from the andapos end region are sufficient to indicate gene expression levels All andapos end sequencing methods have revealed that most eukaryotic genes display a ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Aptamers and BSI for Sub-Microliter Analysis of Pharmaceuticals in Neonatal Urine

    SBC: BASE PAIR BIOTECHNOLOGIES INC            Topic: NICHD

    DESCRIPTION provided by applicant Neonatal and pediatric intensive care still involves performing painful needle punctures to obtain blood samples for routine clinical monitoring Pain management in the neonatal setting is often achieved by long term continuous intravenous infusion of morphine or related compounds It has become increasingly clear however that long term use of opioid compound ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. An eHealth solution for posttraumatic stress and pain screening integrated in pediatric injury care

    SBC: Radiant Creative Group, LLC            Topic: NICHD

    DESCRIPTION provided by applicant Each year million US children are injured affecting the child his her family and society which often bears the cost Among school age children age to injuries lead to million emergency department ED visits and hospital admissions annually resulting in $ billion in medical costs and $ billion more in work loss costs Approxima ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Optimized lactoferrin for treatment of intracerebral hemorrhage

    SBC: Pharmareview Corporation            Topic: 101

    DESCRIPTION provided by applicant Intracerebral hemorrhage ICH is a major public health problem with the highest mortality rate of all stroke subtypes ICH is one of the leading causes of long term disability Since there are no available FDA approved therapies for ICH it is of vast importance to search for new approaches in treatment for this devastating medical condition Lactoferrin LT ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Oral Small Molecule STAT3 Inhibitor to Treat Cachexia in Chronic Kidney Disease

    SBC: StemMed, Ltd.            Topic: NIDDK

    DESCRIPTION provided by applicant Chronic kidney disease CKD is a major public health problem in the US with an estimated prevalence of million patients enter hemodialysis or peritoneal dialysis programs yearly A serious complication in of patients with CKD is cachexia or muscle wasting which decreases quality of life and increases morbidity and mortality Unfortunately ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. A sample-to-answer diagnostic cartridge that identifies influenza using a glucometer

    SBC: Paratus Diagnostics            Topic: NIAID

    Project Summary Abstract Seasonal influenza has an annual global incidence of up to in adults and up to in children About to million infections result in severe disease while somewhere between a quarter and a half million cases are fatal Antiviral drugs can lessen the severity and reduce mortality when administered within h of onset of symptoms Hence sensitive and specific poin ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. The Effects of an Oral Nitric Oxide Lozenge on Peripheral Artery Disease

    SBC: Neogenis Laboratories, Inc.            Topic: 213

    Abstract Peripheral artery disease PAD is a common circulatory problem in which narrowed arteries reduce blood flow to your limbs thereby restricting blood flow During exercise or simply walking there is not sufficient blood flow to keep up with the metabolic demand This causes symptoms most notably leg pain when walking intermittent claudication PAD is also likely to be a sign of more w ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government